<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211030052912N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-28</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of Unihemispheric Concurrent Dual-Site Transcranial Direct Current Stimulation of Dorsolateral Prefrontal Cortex AND primary motor cortex on improvement of lower limb motor function in patients with chronic stroke: A double-blind controlled clinical trial</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of Unihemispheric Concurrent Dual-Site Transcranial Direct Current Stimulation of Dorsolateral Prefrontal Cortex AND primary motor cortex on improvement of lower limb motor function in patients with chronic stroke: A double-blind controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>37</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66974</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done through Randomization.com. In this method, according to the two intervention groups (A) and control (B), 6 blocks of 4 will be determined. Each sequence is then recorded on a card and placed in an envelope. In order of patients' arrival, the envelopes are opened and the assigned group of the participant is determined. In this double-blind study, patients and evaluators are unaware of the type of group assigned. Randomization and intervention will be performed by a person who is not involved in the patient evaluation process and the evaluator is unaware of the type of intervention, Blinding description: In order to protect patients 'personal information, patients' names and the type of study group are entered in a booklet along with a numeric code that has nothing to do with the national code or ID number, and all information in the computer and forms and analyzes are based on that numeric code. And the booklet will only be kept safe by the researcher and out of reach of others, and the information reported in the research will not be such that the identity of patients can be ascertained.
At the beginning of the implementation, all patients are informed that they may be in the intervention or control group, but will be unaware of this issue until the end of the project. After extracting the data, if the intervention is effective, the control group will be called and effective intervention for them. In addition to the patients, the person analyzing the MRS results (evaluator) is also unaware. Randomization and intervention will be performed by a person who is not involved in the patient evaluation process.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Stroke.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Anodal stimulation of the M1 and DLPFC of the involved side. The two-channel device 2-NEUROSTIM manufactured by Medina Medical Company will be used to create electrical brain movements. The location of the electrodes will be determined using the international 10-20 system of electroencephalography. The location of the electrodes is determined using an international system of 10-20 electroencephalographs. The electrode pads are soaked in saline. Active electrodes according to the involved side, is left M1( c3) and DLPFC( F3) or right m1 (c4) and DLPFC ( F4 ) and reference electrodes will be placed on the contralateral of superorbital . Constant current with an intensity of 1 mA for 20 minutes with active electrode of 16 cm2 and a reference electrode of 35 cm2 will be used.The electrical stimulation will last for 5 sessions. After stimulating the patient, he will perform routine upper extremity exercises. Intervention 2: Control group: real M1 anal stimulation and sham DLPFC on the involved side. To generate brain electrical stimulations, the 2-NEUROSTIM two-channel device manufactured by Medina Tabgaster Company will be used. The location of the electrodes is determined using the international 10-20 electroencephalography system . The electrode pad is soaked in physiological serum solution. Active electrodes according to the involved side in the areas of the primary motor cortex equivalent to c3 and the posterior-lateral prefrontal cortex equivalent to F3 (in the left involvement) or the primary motor cortex equivalent to c4 and the posterior-lateral prefrontal cortex equivalent to F4 (right involvement) and reference electrodes on They will be placed on the supraorbital of the uninvolved side. A constant current with an intensity of 1 milliampere is applied for 20 minutes in a real way on the c3/c4 area and as a sham on the F3/F4 area. In order to localize the excitability of the motor cortex, the active electrode of 16 cm2 and the reference electrode of 35 cm2 will be used. Electrical stimulation will be for 5 sessions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Confidentiality of data</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Somaye Azarnia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Guilan University of Medical Sciences' Headquarters,  Parastar St., Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>13111-41937</zip>
        <telephone>+98 13 3334 6489</telephone>
        <email>azarnia.pt.82@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Azarnia Somaye</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No .10, Shahid Nazari Ave, Shahid Beheshti Blvd., Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4188866449</zip>
        <telephone>+98 13 3360 5990</telephone>
        <email>azarnia.pt.82@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>First stroke
Medial Cerebellar Artery (MCA) stroke
The ability to verbally communicate with the therapist
Patients using the Ashworth Modified  Modified Scale (MMAS) to have a knee flexion muscle spasm severity of 1 or higher
No history of a brain tumor
Patients who do not have severe cognitive and memory disorders. To determine this, the Persian version of the  Mini-Mental State Examination  is used and patients must score at least 23 out of a total of 30</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with chronic neurological diseases such as Parkinson's, Alzheimer's, schizophrenia, radiculopathy, and musculoskeletal disorders, especially upper extremity movement disorders, diagnosed by a neurologist.
History of seizures, previous brain surgery, heart disease and pacemaker
Take drugs that change a person's cognitive status</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G46</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Vascular syndromes of brain in cerebrovascular diseases</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Anodal stimulation of the M1 and DLPFC of the involved side. The two-channel device 2-NEUROSTIM manufactured by Medina Medical Company will be used to create electrical brain movements. The location of the electrodes will be determined using the international 10-20 system of electroencephalography. The location of the electrodes is determined using an international system of 10-20 electroencephalographs. The electrode pads are soaked in saline. Active electrodes according to the involved side, is left M1( c3) and DLPFC( F3) or right m1 (c4) and DLPFC ( F4 ) and reference electrodes will be placed on the contralateral of superorbital . Constant current with an intensity of 1 mA for 20 minutes with active electrode of 16 cm2 and a reference electrode of 35 cm2 will be used.The electrical stimulation will last for 5 sessions. After stimulating the patient, he will perform routine upper extremity exercises.</i_keyword>
      <i_keyword>Control group: real M1 anal stimulation and sham DLPFC on the involved side. To generate brain electrical stimulations, the 2-NEUROSTIM two-channel device manufactured by Medina Tabgaster Company will be used. The location of the electrodes is determined using the international 10-20 electroencephalography system . The electrode pad is soaked in physiological serum solution. Active electrodes according to the involved side in the areas of the primary motor cortex equivalent to c3 and the posterior-lateral prefrontal cortex equivalent to F3 (in the left involvement) or the primary motor cortex equivalent to c4 and the posterior-lateral prefrontal cortex equivalent to F4 (right involvement) and reference electrodes on They will be placed on the supraorbital of the uninvolved side. A constant current with an intensity of 1 milliampere is applied for 20 minutes in a real way on the c3/c4 area and as a sham on the F3/F4 area. In order to localize the excitability of the motor cortex, the active electrode of 16 cm2 and the reference electrode of 35 cm2 will be used. Electrical stimulation will be for 5 sessions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Motor function. Timepoint: Before  the first and after last electrical stimulation. Method of measurement: Fugl meyer test.</prim_outcome>
      <prim_outcome>Brain metabolite activity,. Timepoint: Before  the first and after last electrical stimulation. Method of measurement: Metabolite content  with Magnetic resonance imaging.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-09</approval_date>
        <contact_name>Ethics Committee of the Guilan University of Medical Sciences</contact_name>
        <contact_address>Namjoo avenue Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
